Horizon Technology Finance Prices $57.5 Million Notes Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: Newsfilter
- Bond Offering Size: Horizon Technology Finance Corporation successfully priced a $57.5 million offering of 7.00% Notes due 2028, demonstrating the company's ability to access capital markets effectively.
- Interest Rate and Repayment Terms: The Notes carry an annual interest rate of 7.00%, with interest payments scheduled for June 15 and December 15 each year, providing a stable cash flow to support the company's financial health.
- Use of Proceeds: The company intends to use the net proceeds from this offering to repay existing debt, including its 4.875% Notes due 2026, aiming to optimize its capital structure and reduce financial costs.
- Market Positioning: As a specialty finance company focused on technology and life sciences, Horizon strengthens its position in the venture capital and private equity markets through this bond issuance.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like HRZN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on HRZN
Wall Street analysts forecast HRZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRZN is 6.67 USD with a low forecast of 6.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
1 Hold
1 Sell
Hold
Current: 6.670
Low
6.00
Averages
6.67
High
7.50
Current: 6.670
Low
6.00
Averages
6.67
High
7.50
About HRZN
Horizon Technology Finance Corporation is a specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries. The Company's investment objective is to maximize its investment portfolio’s return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It is focused on making secured debt investments to venture capital and private equity-backed companies and publicly traded companies in its target industries. It seeks to invest in companies that vary by their stage of development, their target industries and sectors of target industries and their geographical location, as well as by the venture capital and private equity sponsors that support its portfolio companies. The Company’s adviser is Horizon Technology Finance Management LLC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Horizon Technology Finance Provides $50 Million Loan Facility to Pelthos Therapeutics
- Financing Support: Horizon Technology Finance has provided a $50 million venture loan facility to Pelthos Therapeutics, with an initial funding of $30 million and up to $20 million for future growth, reflecting confidence in Pelthos' innovative products.
- Product Innovation: Pelthos' ZELSUVMI™ (berdazimer) topical gel has received FDA approval for treating molluscum contagiosum, offering a new at-home treatment option that could transform patient care approaches.
- Market Expansion: Pelthos has also acquired rights to Xepi® Cream and Xeglyze®, with the loan proceeds aimed at promoting these products, facilitating further expansion in the dermatology market.
- Strategic Partnership: Horizon's CIO Paul Seitz noted that this financing will assist Pelthos in promoting its products within pediatric and dermatologic communities, further driving business growth and showcasing Horizon's expertise in the life sciences sector.
Continue Reading
Horizon Technology Finance Corp Prices $57.5M Notes Offering with 19.61% Dividend Yield
- Attractive Dividend Yield: Horizon Technology Finance Corp offers a 19.61% dividend yield, showcasing its strong free cash flow and commitment to shareholder returns, which enhances market interest in its stock.
- Analyst Rating Changes: Maxim Group analyst Michael Diana maintained a Buy rating but lowered the price target from $10 to $7.5, reflecting a cautious outlook on future market performance despite a 56% accuracy rate.
- Financial Update: On December 11, 2025, Horizon Technology Finance priced a $57.5 million offering of 7.00% notes, which is expected to provide stable cash inflows to support future investments and operations.
- Market Reaction: Benzinga Pro's real-time news alerts investors to the latest developments regarding Horizon Technology Finance, indicating sustained market interest in high-yield stocks, especially amid economic uncertainty.
Continue Reading